Comparative analysis of the ERα/ERβ ratio and neurotensin and its high-affinity receptor in myometrium, uterine leiomyoma, atypical leiomyoma, and leiomyosarcoma

International Journal of Gynecological Pathology

Volumn 30, Issue 4, 2011, Pages 354-363

  Rodríguez, Yurena ^a,e   Báez, Delia ^b,e   De Oca, Francisco Montes ^d   García, Candelaria ^c,e   Dorta, Idaira ^a,e   Reyes, Ricardo ^a,e   Valladares, Francisco ^b,e   Almeida, Teresa A ^a,e   Bello, Aixa R ^a,e  

^a UNIVERSIDAD DE LA LAGUNA   (Spain)

^b UNIVERSIDAD DE LA LAGUNA   (Spain)

^c HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

^d Hospital La Colina (USP)   (Spain)

^e Madrid Spain   (Spain)

Author keywords

Atypical leiomyoma; Estrogen receptors; Leiomyosarcoma; Neurotensin; Neurotensin receptor 1

Indexed keywords

ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; MESSENGER RNA; NEUROTENSIN; NEUROTENSIN RECEPTOR; NEUROTENSIN RECEPTOR 1; UNCLASSIFIED DRUG;

ARTICLE; ATYPICAL LEIOMYOMA; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; COMPARATIVE STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LEIOMYOMA; LEIOMYOSARCOMA; MYOMETRIUM; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR AFFINITY; UTERUS MYOMA;

CELL NUCLEUS; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LEIOMYOMA; LEIOMYOSARCOMA; MUSCLE, SMOOTH; MYOMETRIUM; NEUROTENSIN; RECEPTORS, NEUROTENSIN; UTERINE NEOPLASMS;

EID: 79958797526     PISSN: 02771691     EISSN: 15387151     Source Type: Journal    
DOI: 10.1097/PGP.0b013e31820918cb     Document Type: Article

References (38)

1. Okolo S. Incidence, aetiology and epidemiology of uterine fibroids. Best Pract Res Clin Obstet Gynaecol 2008;22:571-88. (Pubitemid 351804127)
2. Yavuz E, Güllüoǧlu MG, Akbaş N, et al. The values of intratumoral mast cell count and Ki-67 immunoreactivity index in differential diagnosis of uterine smooth muscle neoplasms. Pathol Int 2001;51:938-41. (Pubitemid 34175521)
3. Sung CO, Ahn G, Song SY, et al. Atypical leiomyomas of the uterus with long-term follow-up after myomectomy with immunohistochemical analysis for p16INK4A, p53, Ki-67, estrogen receptors, and progesterone receptors. Int J Gynecol Pathol 2009;28:529-34.
4. Giuntoli RL, Gostout BS, DiMarco CS, et al. Diagnostic criteria for uterine smooth muscle tumors: leiomyoma variants associated with malignant behavior. J Reprod Med 2007;52:1001-10. (Pubitemid 350305082)
5. Sun X, Mittal K. MIB-1 (Ki-67), estrogen receptor, progesterone receptor, and p53 expression in atypical cells in uterine symplastic leiomyomas. Int J Gynecol Pathol 2010;29:51-4.
6. Singh AM, Konjengbam R, Devi SS, et al. Leiomyosarcoma of uterus-a case report. J Indian Med Assoc 2006;104:142-7.
7. Hyder SM, Stancel GM. Regulation of angiogenic growth factors in the female reproductive tract by estrogens and progestins. Mol Endocrinol 1999;13:806-11. (Pubitemid 30645298)
8. Björnström L, Sjöberg M. Mechanisms of estrogen receptor signaling: convergence of genomic and nongenomic actions on target genes. Mol Endocrinol 2005;19:833-42. (Pubitemid 40397050)
9. Taylor SE, Martin-Hirsch PL, Martin FL. Oestrogen receptor splice variants in the pathogenesis of disease. Cancer Lett 2010;288:133-48.
10. Chen GG, Zeng Q, Tse GM. Estrogen and its receptors in cancer. Med Res Rev 2008;28:954-74.
11. Shaaban AM, Speirs V. The estrogen receptors alpha, beta, and beta cx. Clin Cancer Res 2005;11:8222; author reply 8222-3.
12. Jongen V, Briët J, de Jong R, et al. Expression of estrogen receptor-alpha and -beta and progesterone receptor-A and -B in a large cohort of patients with endometrioid endometrial cancer. Gynecol Oncol 2009;112:537-42.
13. Mylonas I, Jeschke U, Shabani N, et al. Normal and malignant human endometrium express immunohistochemically estrogen receptor alpha (ER-alpha), estrogen receptor beta (ER-beta) and progesterone receptor (PR). Anticancer Res 2005;25:1679-86.
14. Wang H, Wu X, Englund K, et al. Different expression of estrogen receptors alpha and beta in human myometrium and leiomyoma during the proliferative phase of the menstrual cycle and after GnRHa treatment. Gynecol Endocrinol 2001;15:443-52. (Pubitemid 34098405)
15. Kovács KA, Oszter A, Göcze PM, et al. Comparative analysis of cyclin D1 and oestrogen receptor (alpha and beta) levels in human leiomyoma and adjacent myometrium. Mol Hum Reprod 2001;7:1085-91. (Pubitemid 33040972)
16. Roan C, Chuang J, Hsu T, et al. Estrogen receptor beta is not increasingly expressed in leiomyoma nodules which show no progressive enlargement in premenopausal women. J Formos Med Assoc 2005;104:920-6.
17. Ioffe YJ, Li AJ, Walsh CS, et al. Hormone receptor expression in uterine sarcomas: prognostic and therapeutic roles. Gynecol Oncol 2009;115:466-71.
18. Bello AR, Reyes R, Hernández G, et al. Developmental expression of neurotensin in thyrotropes and gonadotropes of male and female rats. Neuroendocrinology 2004;79:90-9. (Pubitemid 38316501)
19. Alexander MJ, Leeman SE. Estrogen-inducible neurotensin immunoreactivity in the preoptic area of the female rat. J Comp Neurol 1994;345:496-509.
20. Dupouy S, Viardot-Foucault V, Alifano M, et al. The neurotensin receptor-1 pathway contributes to human ductal breast cancer progression. PLoS ONE 2009;4:e4223.
21. Reubi JC, Waser B, Schaer JC, et al. Neurotensin receptors in human neoplasms: high incidence in Ewing's sarcomas. Int J Cancer 1999;82:213-8. (Pubitemid 29293780)
22. Elek J, Pinzon W, Park KH, et al. Relevant genomics of neurotensin receptor in cancer. Anticancer Res 2000;20:53-8. (Pubitemid 30189733)
23. Sehgal I, Powers S, Huntley B, et al. Neurotensin is an autocrine trophic factor stimulated by androgen withdrawal in human prostate cancer. Proc Natl Acad Sci U S A 1994;91:4673-7. (Pubitemid 24177711)
24. Seethalakshmi L, Mitra SP, Dobner PR, et al. Neurotensin receptor expression in prostate cancer cell line and growth effect of NT at physiological concentrations. Prostate 1997;31:183-92. (Pubitemid 27225203)
25. Carraway RE, Hassan S. Neurotensin receptor binding and neurotensin-induced growth signaling in prostate cancer PC3 cells are sensitive to metabolic stress. Regul Pept 2007;141:140-53. (Pubitemid 46482701)
26. Carraway RE, Plona AM. Involvement of neurotensin in cancer growth: evidence, mechanisms and development of diagnostic tools. Peptides 2006;27:2445-60. (Pubitemid 44402788)
27. Rodríguez Y, Almeida TA, Valladares F, et al. Neurotensin and neurotensin receptor 1 expression in human myometrium and uterine leiomyomas. Biol Reprod 2010;83:641-7.
28. Tavassoli FA, Devilee P, eds. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Breast and Female Genital Organs. Tumours of the Uterine Corpus. Lyon: IARC Press; 2003:217-57.
29. Studler JM, Kitabgi P, Tramu G, et al. Extensive co-localization of neurotensin with dopamine in rat meso-cortico-frontal dopaminergic neurons. Neuropeptides 1988;11:95-100. (Pubitemid 18095023)
30. Tramu G, Pillez A, Leonardelli J. An efficient method of antibody elution for the successive or simultaneous localization of two antigens by immunocytochemistry. J Histochem Cytochem 1978;26:322-4. (Pubitemid 8328030)
31. D'Angelo E, Spagnoli LG, Prat J. Comparative clinicopathologic and immunohistochemical analysis of uterine sarcomas diagnosed using the World Health Organization classification system. Hum Pathol 2009;40:1571-85.
32. Valladares F, Frías I, Báez D, et al. Characterization of estrogen receptors alpha and beta in uterine leiomyoma cells. Fertil Steril 2006;86:1736-43.
33. Wärnmark A, Wikström A, Wright AP, et al. The N-terminal regions of estrogen receptor alpha and beta are unstructured in vitro and show different TBP binding properties. J Biol Chem 2001;276:45939-44.
34. Bodner K, Bodner-Adler B, Kimberger O, et al. Estrogen and progesterone receptor expression in patients with uterine smooth muscle tumors. Fertil Steril 2004;81:1062-6. (Pubitemid 38452974)
35. Zhang G, Liu X, Farkas AM, et al. Estrogen receptor beta functions through nongenomic mechanisms in lung cancer cells. Mol Endocrinol 2009;23:146-56.
36. Ip PP, Tse KY, Tam KF. Uterine smooth muscle tumors other than the ordinary leiomyomas and leiomyosarcomas: a review of selected variants with emphasis on recent advances and unusual morphology that may cause concern for malignancy. Adv Anat Pathol 2010;17:91-112.
37. Akhan SE, Yavuz E, Tecer A, et al. The expression of Ki-67, p53, estrogen and progesterone receptors affecting survival in uterine leiomyosarcomas. A clinicopathologic study. Gynecol Oncol 2005;99:36-42.
38. Raspollini MR, Amunni G, Villanucci A, et al. Estrogen and progesterone receptors expression in uterine malignant smooth muscle tumors: correlation with clinical outcome. J Chemother 2003;15:596-602. (Pubitemid 38241410)